Skip to main content
Premium Trial:

Request an Annual Quote

HTG Validating PROOF Centre's Heart Transplant Rejection Assay

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.

HTG will use the HTG Edge System in the clinical laboratory of St. Paul's Hospital, Providence Health Care in Vancouver, British Columbia to start clinical validation of the PROOF Centre's molecular biomarker test, which is intended to help physicians better monitor and treat patients after a heart transplant.

HTG's platform automates RNA analysis and delivers extraction-free, multiplexed results on a number of biological samples in 24 hours, the Tucson, Ariz.-based company said, adding the HTG Edge System enables the analysis of up to 47 different genes from minimal specimen volume.

The terms of the deal also call for the PROOF Centre to work with HTG to prepare for regulatory approval in North America. Funding for clinical validation of the assay is provided by the PROOF Centre, Genome British Columbia, Provincial Health Services Authority, Providence Health Care Research Institute, Vancouver Coastal Health Research Institute, and the Transplant Research Foundation of BC.

"This collaboration with PROOF will result in the timely and localized assessment of a patient's heart failure risk due to rejection," HTG CEO TJ Johnson said in a statement. "The marriage of HTG Edge RNA analysis platform and PROOF Centre's meticulous research will provide a testing mechanism to replace technology now available only at specialty laboratories."

Last November, HTG said it was licensing technology from the PROOF Centre to develop and commercialize a COPD test.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.